All In Biotech

Drug Trial Radar · NCT06812078

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Feb 7, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Conditions

  • Idiopathic Hypersomnia

Interventions

  • TAK-360Drug

    TAK-360 tablet.

  • PlaceboOther

    TAK-360 matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 8

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Takeda Site 11

    Redwood City, California · Recruiting

  • Takeda Site 10

    Santa Ana, California · Recruiting

  • Takeda Site 27

    Colorado Springs, Colorado · Recruiting

  • Takeda Site 19

    Brandon, Florida · Recruiting

  • Takeda Site 14

    Winter Park, Florida · Recruiting

  • Takeda Site 29

    St Louis, Missouri · Recruiting

  • Takeda Site 16

    Denver, North Carolina · Recruiting

  • Takeda Site 15

    Huntersville, North Carolina · Recruiting

  • Takeda Site 12

    Cincinnati, Ohio · Recruiting

  • Takeda Site 17

    Cincinnati, Ohio · Recruiting

  • Takeda Site 13

    Columbia, South Carolina · Recruiting

  • Takeda Site 18

    San Antonio, Texas · Recruiting

  • Takeda Site 28

    Norfolk, Virginia · Recruiting

  • Takeda Site 2

    Paris, France · Recruiting

  • Takeda Site 1

    Montpellier, Hrault, France · Recruiting

  • Takeda Site 3

    Nantes, Pays de Loire, France · Recruiting

  • Takeda Site 4

    Shatin, Hong Kong · Withdrawn

  • Takeda Site 5

    Bologna, Italy · Recruiting

  • Takeda Site 6

    Pozzilli, Isernia, Italy · Recruiting

  • Takeda Site 7

    Rome, Roma, Italy · Recruiting

  • Takeda Site 26

    Verona, Veneto, Italy · Recruiting

  • Takeda Site 25

    Fukuoka-Shi Hakata-Ku, Fukuoka, Japan · Recruiting

  • Takeda Site 23

    Kurume-shi, Fukuoka, Japan · Recruiting

  • Takeda Site 22

    Kohoku-ku, Yokohama-Shi, Kanagawa, Japan · Recruiting

  • Takeda Site 20

    Kumamoto, Kumamoto, Japan · Recruiting

  • Takeda Site 21

    Yodogawa-ku, Osaka-shi, Osaka, Japan · Recruiting

  • Takeda Site 24

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Takeda Site 8

    Madrid, Spain · Recruiting

  • Takeda Site 9

    Vitoria-Gasteiz, Alava, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.